Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-11-17 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material events or information. The document does not contain financial statements, detailed financial analysis, or comprehensive report data. It is a regulatory disclosure of a significant corporate event (FDA approval) rather than a financial report or detailed investor presentation. The document length is 4366 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-11-17 English
Transcript of the Q2 FY2024 Earnings Conference Call.
Call Transcript Classification · 100% confidence The document is a transcript of the Q2 FY2024 earnings conference call for Lupin Limited, dated November 9, 2023. It includes detailed discussions by management on quarterly financial results, business performance, product launches, geographic segment growth, margins, R&D expenses, and outlook. The presence of a Q&A session further confirms it is a full transcript of an earnings call. The document references specific quarterly financial data and management commentary, which aligns with the definition of a Call Transcript (CT). The length of the document (15,000 characters) and the detailed content confirm it is not a brief announcement or summary but a full transcript. Therefore, the appropriate classification is Call Transcript (CT).
2023-11-17 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q2 FY2024 earnings conference call for Lupin Limited, dated November 9, 2023. It includes management commentary on financial performance, business segments, product launches, revenue growth, margins, and outlook, followed by a Q&A session with analysts. The presence of detailed financial figures, management discussion, and Q&A confirms this is a full earnings call transcript rather than a brief earnings release or summary. The document references the SEBI regulations for disclosure and explicitly states it is a transcript of the earnings conference call. Therefore, the appropriate classification is Call Transcript (CT).
2023-11-17 English
Lupin and Amman Pharma Sign Exclusive Licensing and Supply Agreement for Ranibizumab Biosimilar.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a partnership agreement between Lupin Limited and Amman Pharmaceuticals Industries for exclusive marketing and commercialization of a biosimilar drug in the Middle East region. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The content focuses on a business collaboration and licensing agreement rather than financial results, management changes, or regulatory filings. The document length is about 6,878 characters, which is consistent with a detailed press release but does not contain financial statements or detailed financial data. It is not an earnings release, annual report, or management discussion. It is a corporate announcement about a partnership/licensing deal, which fits best under Capital/Financing Update (CAP) as it relates to a significant commercial agreement impacting the company's business and potentially its capital or revenue streams. Therefore, the appropriate classification is CAP with high confidence.
2023-11-10 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a partnership agreement between Lupin Limited and Amman Pharmaceuticals Industries for exclusive marketing and commercialization of a biosimilar drug in the Middle East region. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The content focuses on the business collaboration and product details, not on financial results, management changes, or regulatory filings. The document is not a financial report, earnings release, or management discussion, nor is it a voting result or capital change announcement. It is a corporate announcement about a business development event. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to a significant business partnership and commercialization agreement impacting the company's operations and potential revenue streams.
2023-11-10 English
Audio recording of the Earnings Call - Q2 FY24.
Call Transcript Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about the hosting of the audio recording of the Earnings Call for Q2 FY24 on the company's website. It references the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating a regulatory compliance announcement. The document does not contain the transcript or detailed financial data but merely announces the availability of the earnings call audio recording. The document length is short (1653 characters), and it is an announcement rather than the actual earnings release or transcript. Therefore, the appropriate classification is Call Transcript (CT), as it relates directly to the earnings call audio recording, which is a form of call transcript material.
2023-11-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.